AIDS Investigators Cautiously Applauding Recent Advances

Discoveries announced at conference leave scientists feeling optimistic; yet their enthusiasm is tempered by several persistent concerns. AIDS researchers have many reasons to be encouraged. Studies show that treatments combining new and old drugs can control HIV levels in the blood. Moreover, many scientists and activists note, prevention efforts have helped reduce HIV infection rates. Yet the enthusiasm is tempered by several caveats. Drugs are expensive and have harsh side effects, leading

Written bySteven Benowitz
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share


Discoveries announced at conference leave scientists feeling optimistic; yet their enthusiasm is tempered by several persistent concerns.
AIDS researchers have many reasons to be encouraged. Studies show that treatments combining new and old drugs can control HIV levels in the blood. Moreover, many scientists and activists note, prevention efforts have helped reduce HIV infection rates. Yet the enthusiasm is tempered by several caveats. Drugs are expensive and have harsh side effects, leading some to believe the only way to win the war against AIDS is with a vaccine. Resistance continues to be a concern. And no one has shown long-term benefit -- whether these drugs can delay onset of disease or prolong life. What's more, there is little evidence that the virus can be eradicated from the body.

Still, optimism is running high about recent advances in AIDS research, news of which was the highlight of the 11th International Conference ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies